Mechanisms of immunomodulatory action of intravenous immunoglobulin in autoimmune and systemic inflammatory diseases

Therapeutic Apheresis

Volumn 1, Issue 1, 1997, Pages 38-41

  Vassilev, Tchavdar ^a   Kazatchkine, Michel D ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

Autoimmunity; IgG; Immune networks; Immunotherapy

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT;

ANIMAL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; EDITORIAL; HUMAN; IMMUNOLOGY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0031061212     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-9987.1997.tb00011.x     Document Type: Article

References (22)

1. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-16.
2. Mouthon L, Kaveri SV, Kazatchkine MD. Immune modulating effects of intravenous immunoglobulins (IVIg) in autoimmune diseases. Tranfus Sci 1994;15:393-408.
3. Kazatchkine MD, Dietrich G, Hurez V, Ronda N, Bellon B, Rossi F, Kaveri SV. V Region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 1994;139:79-107.
4. Imbach P, Morell A. Idiopathic trombocytopenic purpura (ITP): Immunomodulation by intravenous immunoglobulin (IVIg). Int Rev Immunol 1989;5:181-8.
5. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders RP. The treatment of Kawasaki syndrome with intravenous gammaglobulin. N Engl J Med 1986;315:341-7.
6. Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD. Mechanisms of action of intravenous immune globulins in immune-mediated diseases. Clin Exp Immunol 1996;104(suppl 1):3-9.
7. Debré M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, Vilmer E, Caplan C, Teillaud JL, Griscelli C. Infusion of Fcg fragments for the treatment of children with acute immune thrombocytopenic purpura. Lancet 1993;342: 945-9.
8. Basta M, Langlois PF, Marques M, Frank MM, Fries LF. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989;74:326-33.
9. Basta M, Fries LF, Frank MM. High-dose intravenous immunoglobulin inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991;77:376-80.
10. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complements fragments. J Clin Invest 1994;94:1729-35.
11. Andersson UG, Bjork L, Skansén-Saphir U, Andersson JP. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994;139:21-42.
12. Hashimoto F, Sakiyama Y, Matsumoto S. The suppressive effect of gammaglobulin preparations on in vitro pokeweed mitogen-induced immunoglobulin production. Clin Exp Immunol 1986;65:409-15.
13. Amran A, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependant human T-cell proliferation by intravenous immunoglobulin. Clin Imnmnol Immunopathol 1994;73:180-6.
14. Van Shaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent Immunoglobulin for Intravenous Use Interferes with cell proliferation in vitro. J Clin Immunol 1992;12:325-34.
15. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993;92:369-72.
16. Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, Kazatchkine MD. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (intravenous immunoglobulin, IVIg). Ther Immunol 1994;1:269-78.
17. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, Pouletty P, Glotz D, Kazatchkine MD. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg). J Clin Invest 1996;97:865-9.
18. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schlutter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proc Natl Acad Sci USA 1992;89:3325-9.
19. Gaur A, Fathman CG. Immunotherapeutic strategies directed at the trimolecular complex. Adv Immunol 1994;56:219-65.
20. Adib M, Ragimbeau J, Avrameas S, Ternynck T. IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol 1990;145:3807-13.
21. Hurez V, Kaveri SV, Kazatchkine MD. Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol 1993;23:783-9.
22. Rossi F, Jayne DRW, Lockwood CM, Kazatchkine MD. Antiidiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991;83:298-303.